DVL1 and schizophrenia: A significant reduction in GSK3β [232], but not in β-catenin or Dvl-2 levels [233], was found post-mortem in the prefrontal cortex of 10 patients with schizophrenia, compared to 10 controls; however, this was not replicated when the same group of investigators extended their sample to 15 and compared it with 15 patients with bipolar disorder, 15 with unipolar depression and 15 with non-psychiatric conditions, with GSK-3β, β-catenin and Dvl-2 not differing among the groups [234].